PLoS ONE:靶向FGFR4能够抑制肝细胞癌

2012-05-24 Deepblue 生物谷

近日,来自美国基因泰克公司的研究人员表示,靶向FGFR4能够抑制肝细胞癌。 成纤维细胞生长因子(FGF)是由垂体和下丘脑分泌的多肽,能促进成纤维细胞有丝分裂、中胚层细胞的生长,还可刺激血管形成,在创伤愈合及肢体再生中发挥重要作用。 FGF受体(FGFR)信号系统对正常的发育及生理过程具有至关重要的作用。业已证明,FGF-FGFR信号失调与肿瘤发生及演化息息相关。在老鼠体内,FGFR4–FGF1

近日,来自美国基因泰克公司的研究人员表示,靶向FGFR4能够抑制肝细胞癌。

成纤维细胞生长因子(FGF)是由垂体和下丘脑分泌的多肽,能促进成纤维细胞有丝分裂、中胚层细胞的生长,还可刺激血管形成,在创伤愈合及肢体再生中发挥重要作用。

FGF受体(FGFR)信号系统对正常的发育及生理过程具有至关重要的作用。业已证明,FGF-FGFR信号失调与肿瘤发生及演化息息相关。在老鼠体内,FGFR4–FGF19信号轴已经被发现与肝细胞癌(HCCs)紧密相关,可能在人类也是如此。

在这项研究里,他们发现FGFR4被需要于肝癌的发生。FGF19转基因小鼠的后代能够发展为HCCs,然而,与FGFR4敲除的老鼠所繁殖的后代不会发展为肝癌。

为了进一步研究FGFR4对肝细胞癌的重要性,他们发展了一个抗FGFR4的单克隆抗体(LD1)。LD1能够抑制FGF1和FGF19结合到FGFR4;还能抑制FGFR4介导的信号、集落形成以及体外增生;也能抑制肿瘤以癌症潜伏期模式生长。

结果发现,对比于正常组织,在包括肝癌的几种类型的癌症,FGFR4表达被明显提高。

Benjamin C. Lin表示,该研究阐明了肝细胞癌的发展及演化中FGFR4的调节作用,而FGFR4很有可能成为一个重要的癌症治疗靶点。(生物谷Deepblue)

doi: 10.1371/journal.pone.0036713
PMC:
PMID:

Targeting FGFR4 Inhibits Hepatocellular Carcinoma in Preclinical Mouse Models

Dorothy M. French, Benjamin C. Lin*, Manping Wang, Camellia Adams, Theresa Shek, Kathy Htzel, Brad Bolon, Ronald Ferrando, Craig Blackmore, Kurt Schroeder, Luis A. Rodriguez, Maria Hristopoulos, Rayna Venook, Avi Ashkenazi, Luc R. Desnoyers.

The fibroblast growth factor (FGF)-FGF receptor (FGFR) signaling system plays critical roles in a variety of normal developmental and physiological processes.It is also well documented that dysregulation of FGF-FGFR signaling may have important roles in tumor development and progression. The FGFR4–FGF19 signaling axis has been implicated in the development of hepatocellular carcinomas (HCCs) in mice, and potentially in humans.In this study, we demonstrate that FGFR4 is required for hepatocarcinogenesis; the progeny of FGF19 transgenic mice, which have previously been shown to develop HCCs, bred with FGFR4 knockout mice fail to develop liver tumors.To further test the importance of FGFR4 in HCC, we developed a blocking anti-FGFR4 monoclonal antibody (LD1). LD1 inhibited: 1) FGF1 and FGF19 binding to FGFR4, 2) FGFR4–mediated signaling, colony formation, and proliferation in vitro, and 3) tumor growth in a preclinical model of liver cancer in vivo.Finally, we show that FGFR4 expression is elevated in several types of cancer, including liver cancer, as compared to normal tissues.These findings suggest a modulatory role for FGFR4 in the development and progression of hepatocellular carcinoma and that FGFR4 may be an important and novel therapeutic target in treating this disease.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1789428, encodeId=c6bd1e894287a, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Aug 10 05:58:00 CST 2012, time=2012-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863188, encodeId=29081863188f9, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sat Feb 09 00:58:00 CST 2013, time=2013-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978317, encodeId=18ea19e8317af, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sat Sep 29 09:58:00 CST 2012, time=2012-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483053, encodeId=2556148305379, content=<a href='/topic/show?id=5dcbe397d2' target=_blank style='color:#2F92EE;'>#FGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7397, encryptionId=5dcbe397d2, topicName=FGFR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=31fb7872570, createdName=12498c24m71暂无昵称, createdTime=Sat May 26 08:58:00 CST 2012, time=2012-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534187, encodeId=2cc8153418e7e, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Sat May 26 08:58:00 CST 2012, time=2012-05-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1789428, encodeId=c6bd1e894287a, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Aug 10 05:58:00 CST 2012, time=2012-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863188, encodeId=29081863188f9, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sat Feb 09 00:58:00 CST 2013, time=2013-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978317, encodeId=18ea19e8317af, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sat Sep 29 09:58:00 CST 2012, time=2012-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483053, encodeId=2556148305379, content=<a href='/topic/show?id=5dcbe397d2' target=_blank style='color:#2F92EE;'>#FGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7397, encryptionId=5dcbe397d2, topicName=FGFR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=31fb7872570, createdName=12498c24m71暂无昵称, createdTime=Sat May 26 08:58:00 CST 2012, time=2012-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534187, encodeId=2cc8153418e7e, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Sat May 26 08:58:00 CST 2012, time=2012-05-26, status=1, ipAttribution=)]
    2013-02-09 xjy02
  3. [GetPortalCommentsPageByObjectIdResponse(id=1789428, encodeId=c6bd1e894287a, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Aug 10 05:58:00 CST 2012, time=2012-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863188, encodeId=29081863188f9, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sat Feb 09 00:58:00 CST 2013, time=2013-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978317, encodeId=18ea19e8317af, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sat Sep 29 09:58:00 CST 2012, time=2012-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483053, encodeId=2556148305379, content=<a href='/topic/show?id=5dcbe397d2' target=_blank style='color:#2F92EE;'>#FGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7397, encryptionId=5dcbe397d2, topicName=FGFR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=31fb7872570, createdName=12498c24m71暂无昵称, createdTime=Sat May 26 08:58:00 CST 2012, time=2012-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534187, encodeId=2cc8153418e7e, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Sat May 26 08:58:00 CST 2012, time=2012-05-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1789428, encodeId=c6bd1e894287a, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Aug 10 05:58:00 CST 2012, time=2012-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863188, encodeId=29081863188f9, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sat Feb 09 00:58:00 CST 2013, time=2013-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978317, encodeId=18ea19e8317af, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sat Sep 29 09:58:00 CST 2012, time=2012-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483053, encodeId=2556148305379, content=<a href='/topic/show?id=5dcbe397d2' target=_blank style='color:#2F92EE;'>#FGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7397, encryptionId=5dcbe397d2, topicName=FGFR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=31fb7872570, createdName=12498c24m71暂无昵称, createdTime=Sat May 26 08:58:00 CST 2012, time=2012-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534187, encodeId=2cc8153418e7e, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Sat May 26 08:58:00 CST 2012, time=2012-05-26, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1789428, encodeId=c6bd1e894287a, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Aug 10 05:58:00 CST 2012, time=2012-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863188, encodeId=29081863188f9, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sat Feb 09 00:58:00 CST 2013, time=2013-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978317, encodeId=18ea19e8317af, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sat Sep 29 09:58:00 CST 2012, time=2012-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483053, encodeId=2556148305379, content=<a href='/topic/show?id=5dcbe397d2' target=_blank style='color:#2F92EE;'>#FGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7397, encryptionId=5dcbe397d2, topicName=FGFR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=31fb7872570, createdName=12498c24m71暂无昵称, createdTime=Sat May 26 08:58:00 CST 2012, time=2012-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534187, encodeId=2cc8153418e7e, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Sat May 26 08:58:00 CST 2012, time=2012-05-26, status=1, ipAttribution=)]
    2012-05-26 liuyiping

相关资讯

Cancer Cell:S1PR1-STAT3激活促进骨髓样细胞的促肿瘤转移作用

近来研究表明,骨髓样细胞可使远处器官易于接受扩散肿瘤细胞的集落形成。然而,其具体机制一直不明。5月14日Cancer Cell报道了Hua Yu研究组的论文"S1PR1-STAT3 Signaling Is Crucial for Myeloid Cell Colonization at Future Metastatic Sites"揭示了其分子机制。   研究者发现,在肿瘤细胞中

Science:研究者揭示抑制癌症的新靶点PARP-1

5月11日,刊登在国际著名杂志Science上的一项研究阐明了一种DNA损伤检测酶PARP-1,当这种酶被抑制后,可以有效抵御癌症和其它疾病。来自托马斯杰佛逊大学和杰佛逊金梅尔癌症中心的研究者揭示了新的靶点,包括特殊的锌指结构域,从而来使得特殊药物作用于PARP-1使其丧失活性。研究者希望发现更多副作用较小的特殊PARP-1的抑制子来达到抑制PARP-1的目的,抑制PARP-1的药物目前已证实在治

Lancet:新药dabrafenib或可安全有效地治疗黑色素瘤

一项针对黑色素瘤中常见基因突变的实验性药物研究证实,药物dabrafenib成功地缩小了发生脑转移的黑色素瘤患者的肿瘤病灶,有效率达90%。这项国际临床I期药物试验研究发表在5月18日的国际著名杂志《柳叶刀》(The Lancet)上。 BRAF基因编码丝氨酸/苏氨酸蛋白激酶B-Raf,与细胞生长调控密切相关。在黑色素瘤中,BRAF常常突变引发细胞生长调控紊乱。Dabrafenib针对突变型BR

Sci Transl Med:daclizumab调控调节性T细胞促进肿瘤免疫治疗

调节性T细胞(Tregs)通过防止免疫细胞攻击自身机体对于人体健康有着重要作用。但是,在肿瘤微环境中Tregs细胞却抑制针对肿瘤细胞的免疫反应。由于Tregs 细胞表面表达CD25,Rech等人认为针对CD25的单抗免疫抑制药物daclizumab也许可以清除Tregs 细胞,从而恢复抗肿瘤免疫反应。 他们的假说得到了证实。5月16日国际著名转化医学杂志Science Translational

Gastroenterology :鱼类脂肪酸或可降低肝癌风险

近日,6月刊的《胃肠病学》(Gastroenterology )发表的一项以人口为基础的日本成人研究显示,食用富含n-3多不饱和脂肪酸(n-3 PUFA)的鱼类以及二十碳五烯酸(EPA)、二十二碳五烯酸(DPA)和二十二碳六烯酸(DHA)等n-3 PUFA与肝细胞癌(HCC)发生风险呈剂量依赖性负相关。 长期以来,食用n-3 PUFA被认为可降低多种癌症的发生风险,但对肝癌预防作用的专门研究报道

JCI:康铁邦团队发现新的肝细胞癌治疗靶点CHK1/SYK(L)

近日,来自中山大学肿瘤防治中心的康铁邦教授及其团队发现,在肝细胞癌中,CHK1靶向脾酪氨酸激酶能够促进其水解,则靶向CHK1/SYK(L)通路能成为一个很有潜力的HCC治疗策略。 肝细胞癌(HCC)是目前最流行的恶性肿瘤之一,能够顽强抵抗化疗或放疗。因此,确定HCC新的治疗靶点更是迫在眉睫。 在这项研究里,他们发现,HCC患者的细胞周期检测点激酶1(CHK1)被频繁的过表达,而且这与不良预后结